Analysis and Automation in Early Pharmaceutical Development
For the pharmaceutical industry, the majority of drug candidates explored in early development will never make it to clinical testing, let alone the market – and the point at which a candidate is abandoned may follow years of work and investment. Tackling this inefficiency, through better drug candidate identification, optimization and selection, could have a major positive impact on drug discovery, to the benefit of pharmaceutical companies and patients alike. At Pittcon 2018, taking place in February in Orlando, Florida, the pharmaceutical and technology industries will gather to hear about some of the major developments assisting effective early drug development. This includes topics such as automation. In recent years, this has played a major role, most significantly through the rise of high-throughput screening, and this will only develop further in years to come as robotic technologies advance. There will also be examples of how liquid chromatomegraphy-mass spectrometry has ...